European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Step Pharma SAS, Paris, France

Watch
Step Pharma SAS

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Premium Service
Unlock Dossier
What is a Dossier?
A dossier provides comprehensive company details as a PDF, together with all underlying original publications and original data in one place.
The download feature is exclusively available for our paid plan. Upgrade your account to access:
Quick Dossier
Entire company details as a PDF
Power Dossier
Entire company details along with all original publications / original data bundled in a ZIP file
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more
Learn more
View plans

Name

Step Pharma SAS

Identification

Sirul
Siren 802795906
Chp
Companies House FC039895
Siret
Siret 80279590600014
EUID
FR7501.802795906

Address

101 rue de Sevres, 75006 Paris, France

Corporate purpose

72.11
Research and experimental development on biotechnology

Study, research, development of drugs for human health, provision of services in biotechnology, development, management and commercialization of tools for biological, medical therapeutic or diagnostic use.

Financial performance

Earnings

For this company, Earnings numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Revenue

For this company, Revenue numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Employees

For this company, Employees numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Marketing & Tech

Network

Loading network

Legal Structure

Current legal representatives Legal form information Premium
Premium
1President
1Auditor
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

JOBS AT NORTH DATA

  • Modern Java Developer
Ownership relations Premium + Ownership & Flags add-on
Premium + Ownership & Flags add-on
Portfolio and Investments
One known active shareholding
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Financials

Key Performance Indicators Financial · Mktg & Tech Premium
Premium
Base/share capital
Total assets
Earnings
Revenue
Equity
Equity ratio
Return on equity
Employee number
Revenue per employee
Taxes
Cash on hand
Receivables
Liabilities
Cost of materials
Wages and salaries
Average salaries per employee
Real estate
Total public funding
Number of public fundings
Patents
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans
Financial Statements Interactive sheets with CSV/Excel download Premium
Premium
Balance
from 2017 to 2018
Profit & Loss
from 2017 to 2018
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Publications

31 Jul 2026
Auditor: Ernst & Young · No longer Auditor (2 companies) · Capital: €4,162,695
16 Jul 2026 also 27/07/2025, 25/08/2024, 20/07/2023, 19/07/2022, 20/07/2021, 02/10/2020, 04/08/2019, 09/08/2018, 07/08/2017, 24/08/2016, 14/09/2015
Bulletin officiel des annonces civiles et commerciales
1 Jun 2026 in Hor
EU funding (€2,499,991): Dencatistat, a first-in-class, tumour-agnostic, orally available CTPS1 inhibitor to treat gynaecologic tumours
21 Jan 2026
Patent: Connections
21 Jan 2026
Patent: Connections
9 Jan 2026
Capital: €4,162,695
9 Dec 2025
Capital: €4,162,694
17 Nov 2025 in United Kingdom also 17/11/2025
Full accounts made up to 2023-12-31
23 Jul 2025
Patent: N-(5-(6-ethoxypyrazine-2-YL)pyridine-2-YL)-4-(2-(ethylsulfonamido)pyrimidine-4-YL)tetrahydro-2H-pyran-4-carboxamide ALS inhibitors of human CTPS1 for the treatment of proliferative diseases
19 Feb 2025
Patent: N-(4-(5-chloropyridine-3-YL)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidine-4-YL)butanamide derivatives and similar compounds ALS Human CTPS1 inhibitors for the treatment of proliferative …
15 May 2024
Capital: €2,418,016
7 Feb 2024 in United Kingdom
Annual report for the year ending 31/12/2022 · Balance sheet for 31/12/2022
24 Jan 2024
Capital: €2,213,472
3 Jan 2024
Patent: Aminopyrimidine Derivatives AS CTPS1 Inhibitors
21 Dec 2023
Patent: CTPS1 inhibitors for use IN the treatment of CTPS2-deficient cancer
27 Apr 2023
President: Andrew Edward Pärker
1 Mar 2023
Patent: Combinations of CTPS1 and BCL2 inhibitors for cancer
4 Jan 2023
Patent: Aminopyrimidine/Pyrazine Derivatives AS Ctps1 Inhibitors
30 Oct 2022
Auditor: LCA Audit · Capital: €2,008,926
11 Oct 2022 in United Kingdom
Reg­is­tra­tion: 11/10/2022 · Director (1)
10 Oct 2022
Reg­is­tra­tion: 10/10/2022 · Address · Legal form: SAS, société par actions simplifiée · Name: STEP PHARMA · Segment clas­si­fi­ca­tion
13 Oct 2021
Capital: €1,418,018
2 Jul 2021
Annual report for the year ending 31/12/2020 · Balance sheet for 31/12/2020 · Earnings statement for 31/12/2020
1 Apr 2021
Capital: €1,145,292
27 Oct 2020
Auditor: Cafigex · No longer Auditor: Opsione · Capital: €757,484
18 Sept 2020
Patent: Sulfonamide derivatives as CTPS1 inhibitors
18 Sept 2020
Patent: Sulfonamide inhibitors as CTPS1 inhibitors
16 Sept 2020
Annual report for the year ending 31/12/2019 · Balance sheet for 31/12/2019 · Earnings statement for 31/12/2019
8 Oct 2019
President (1) · No longer President (1) · Capital: €757,484
27 Sept 2019
President (2)
18 Jul 2019
Annual report for the year ending 31/12/2018 · Balance sheet for 31/12/2018 · Earnings statement for 31/12/2018
18 Jul 2019
Annual report for the year ending 31/12/2018 · Balance sheet for 31/12/2018 · Earnings statement for 31/12/2018
20 Feb 2019
Capital: €757,484
21 Dec 2018
Patent
10 Jul 2018
Annual report for the year ending 31/12/2017 · Balance sheet for 31/12/2017 · Earnings statement for 31/12/2017
4 Jun 2018
Patent: Sulfonamide derivatives
23 Mar 2018
Patent: Aminopyrimidine Derivatives as CTPS1 Inhibitors
3 Jan 2018
Capital: €652,939
30 Nov 2017
Patent: Compounds
24 Sept 2017
Capital: €422,762
13 Sept 2017
Auditor: Lison Chouraki Audit SAS
4 Jul 2017
Annual report for the year ending 31/12/2016 · Balance sheet for 31/12/2016 · Earnings statement for 31/12/2016
29 Jul 2016
Capital: €292,304
19 Jul 2016
President (1) · Auditor: Lison Chouraki Audit SAS, Opsione Sàrl
14 Feb 2016
Capital: €129,175
26 Aug 2015
Capital: €105,425
12 Sept 2014
Capital: €67,925
30 Jun 2014
Reg­is­tra­tion: 16/06/2014 · President (1) · Auditor: Lison Chouraki Audit, Opsione · Capital: €4,175.00 · Corporate Purpose
16 May 2014
Reg­is­tra­tion: 16/05/2014 · Address · Legal form: SAS, société par actions simplifiée · Name: STEP PHARMA · Segment clas­si­fi­ca­tion
There are no publications matching your search.

Mentions

25 Sept 2026 in Rne
Reg­is­tra­tion: 16/05/2014 · President: Andrew Edward Pärker · Auditor: Ernst & Young SAS · Capital: €4,162,695 · Segment clas­si­fi­ca­tion · Corporate Purpose
15 Oct 2022 in Chp
Branch office: Step Pharma
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.